Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study
- 1 January 1995
- journal article
- clinical trial
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 49 (6) , 269-277
- https://doi.org/10.1016/0753-3322(96)82642-4
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Regeneration and Repair of Myelinated Fibers in Sural-Nerve Biopsy Specimens from Patients with Diabetic Neuropathy Treated with SorbinilNew England Journal of Medicine, 1988
- Nerve Glucose, Fructose, Sorbitol,myo-Inositol, and Fiber Degeneration and Regeneration in Diabetic NeuropathyNew England Journal of Medicine, 1988
- Glucose-induced Alterations in Nerve Metabolism: Current Perspective on the Pathogenesis of Diabetic Neuropathy and Future Directions for Research and TherapyDiabetes Care, 1985
- Plasma and red cell sorbitol assay in diabetic subjectsActa Diabetologica, 1985
- Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic ratsMetabolism, 1984
- Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: The effect of aldose reductase inhibitionDiabetologia, 1983
- Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic ratsDiabetologia, 1983
- Aldose Reductase Inhibition Improves Nerve Conduction Velocity in Diabetic PatientsNew England Journal of Medicine, 1983
- The Sorbitol Pathway and the Complications of DiabetesNew England Journal of Medicine, 1973
- Effect of Blood Sugar Control on the Accumulation of Sorbitol and Fructose in Nervous TissuesDiabetes, 1972